Obeticholic Acid: First Global Approval

Sa1579 Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Long Term Safety Extension Study of Obeticholic Acid in Primary Biliary Cirrhosis

(2016) Michael H. Trauner et al.   GASTROENTEROLOGY

Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis

(2016) V. Ratziu et al.   JOURNAL OF HEPATOLOGY

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

P0445 : Obeticholic acid, an FXR agonist, reduces hepatic fibrosis in a rat model of toxic cirrhosis

(2015) L.D. Verbeke et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid

(2014) J. R. F. Walters et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY